Diapin Therapeutics

Executive Summary

Diapin Therapeutics is a preclinical-stage biotechnology company spun out from the University of Michigan in 2018, based on the research of Dr. Yuqing (Eugene) Chen. The company is developing RNA and gene therapies for metabolic and cardiovascular diseases, leveraging a proprietary platform that enables targeted delivery and modulation of gene expression. Diapin has secured funding from grants and a strategic partnership with Beijing SL Pharmaceuticals Ltd., supporting its research and development activities. The company's lead program is advancing toward IND-enabling studies, with a focus on addressing unmet medical needs in diseases with high morbidity. Despite being in the early stages, Diapin's technology has potential for broad applicability in genetic medicine. The company operates in Cambridge, Massachusetts, and is privately held.

Upcoming Catalysts (preview)

• H2 2026Announcement of Series A Funding or Strategic Partnership70% success
• 2027IND Filing for Lead Program40% success
• H1 2027Presentation of Preclinical Efficacy Data at Major Conference60% success